# ALK (Anaplastic Lymphoma Kinase): EML4-ALK Fusions, Point Mutations, and Second-Generation TKIs


## Key Takeaways

- Aberrant activation of the Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase, primarily driven by chromosomal translocations (e.g., EML4-ALK in NSCLC, NPM-ALK in ALCL) and point mutations (e.g., F1174L in neuroblastoma), leads to constitutive oncogenic signaling through pathways like JAK-STAT, PI3K/AKT/mTOR, and RAS/MAPK, promoting uncontrolled cell proliferation and survival.
- The genomic locus of *ALK* at 2p23.2-p23.1 is characterized by complex regulatory elements, including a GC-rich promoter and upstream open reading frames (uORFs) in the 5' UTR, with epigenetic modifications like promoter hypomethylation contributing to aberrant overexpression in certain malignancies.
- ALK inhibitors, including first-generation crizotinib and potent second-generation agents like alectinib, ceritinib, and brigatinib, represent a cornerstone of targeted therapy for ALK-driven cancers, demonstrating significant clinical efficacy by blocking the kinase domain's ATP-binding pocket.
- Resistance to ALK inhibitors frequently emerges via on-target mechanisms, such as acquired secondary mutations within the ALK kinase domain (e.g., L1196M, G1202R) that impair drug binding, or off-target mechanisms involving bypass signaling pathway activation or lineage plasticity.
- Diagnostic confirmation of ALK alterations relies on molecular techniques such as fluorescence in situ hybridization (FISH) for gene rearrangements, immunohistochemistry (IHC) for protein expression, and next-generation sequencing (NGS) for detecting fusions and point mutations, guiding therapeutic decisions.
- Third-generation ALK inhibitors like lorlatinib are designed to overcome resistance mutations, particularly the G1202R alteration, and exhibit significant central nervous system penetration, making them crucial for managing brain metastases and refractory disease.

---

## Executive Summary & Key Metadata

The *ALK* gene (Anaplastic Lymphoma Kinase) encodes a receptor tyrosine kinase (RTK) that was initially identified in 1994 as a fusion partner with nucleophosmin (NPM1) in anaplastic large cell lymphoma (ALCL) [1]. Since that discovery, *ALK* has emerged as a critical oncogenic driver across a broad spectrum of malignancies, including non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors (IMTs), neuroblastoma, anaplastic large cell lymphoma, and rare pediatric melanomas [2, 3, 4, 5]. The gene is a hotspot for chromosomal translocations, point mutations, and copy number alterations that lead to constitutive kinase activation and oncogenic signaling [4, 6]. The development of targeted tyrosine kinase inhibitors (TKIs) has revolutionized treatment for *ALK*-positive cancers, with crizotinib as the first-generation agent followed by more potent second-generation inhibitors such as ceritinib, alectinib, and brigatinib [7, 8, 9]. This reference manual provides a comprehensive, biophysically detailed examination of the *ALK* gene, its genomic organization, protein architecture, signaling pathways, pathogenic mutations, [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), and clinical implications.

| **Attribute** | **Details** |
|---|---|
| **HGNC Symbol** | ALK |
| **UniProt Accession** | Q9UMD1 |
| **Representative PDB ID** | 3L9P |
| **Chromosomal Locus** | 2p23.2-p23.1 |
| **Primary Molecular Function** | Receptor tyrosine kinase; signal transduction; regulation of cell proliferation, differentiation, and survival |
| **Disease & Pathology Associations** | ALCL, NSCLC, IMT, neuroblastoma, pediatric melanoma, mesothelioma, papillary thyroid carcinoma, ovarian carcinoma, glioblastoma, prostate small cell carcinoma |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The *ALK* gene is located on the short arm of chromosome 2 at cytogenetic band 2p23.2-p23.1 [1]. The gene spans approximately 728 kilobases (kb) of genomic DNA on the forward strand. The genomic coordinates are approximately chr2:29,192,774-29,921,612 (GRCh38/hg38 assembly). The gene comprises 29 exons that encode a full-length protein of 1,620 amino acids with a predicted molecular weight of approximately 176 kDa [1, 2].

The *ALK* genomic locus is characterized by a complex regulatory architecture. The promoter region contains multiple transcription factor binding sites, including consensus sequences for Sp1, AP-2, and E-box elements. The 5' untranslated region (UTR) is unusually long, spanning approximately 500 base pairs, and contains multiple upstream open reading frames (uORFs) that may regulate translational efficiency. The 3' UTR contains several AU-rich elements (AREs) that contribute to mRNA instability and post-transcriptional regulation.

### 1.2 Promoter Architecture and Enhancer Elements

The *ALK* promoter lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 binding sites that are essential for basal transcriptional activity. DNase I hypersensitivity analysis has identified several enhancer-like elements within the first intron and upstream of the transcription start site. These enhancer regions contain binding sites for neurogenic transcription factors, consistent with the gene's role in neural development [3]. In neuroblastoma cells, the *ALK* promoter is regulated by the transcription factor MYCN, establishing a positive feedback loop where ALK signaling upregulates MYCN expression, which in turn drives *ALK* transcription [4].

### 1.3 Alternative Splicing and Isoforms

Alternative splicing generates multiple *ALK* transcript variants. The predominant full-length isoform (ALK-201, ENST00000389048) encodes the canonical 1,620-amino acid protein. A shorter isoform, ALK-202, lacks exon 18 and produces a truncated protein that retains the extracellular domain but lacks the kinase domain. This isoform may function as a dominant-negative regulator of full-length ALK signaling.

In the context of *ALK* rearrangements, the fusion transcripts are generated through chromosomal translocations or inversions that juxtapose the 3' portion of *ALK* (encoding the intracellular kinase domain) with the 5' portion of various partner genes. The most common fusion in NSCLC is EML4-ALK, resulting from an inversion on chromosome 2p [5]. Multiple EML4-ALK variant transcripts have been described, differing in the breakpoint within EML4. Variant 1 (E13;A20) fuses exon 13 of EML4 to exon 20 of ALK, while variant 3a/b (E6;A20) fuses exon 6 of EML4 to exon 20 of ALK. These variants exhibit differential sensitivity to ALK inhibitors and distinct clinical behaviors [6].

### 1.4 Epigenetic Regulation

DNA methylation analysis of the *ALK* promoter has revealed tissue-specific methylation patterns. In normal adult tissues, the *ALK* promoter is partially methylated, contributing to the low-level expression observed in most adult tissues. In contrast, neuroblastoma and ALCL cells often exhibit promoter hypomethylation, leading to aberrant overexpression [7]. Histone modifications, particularly H3K4me3 and H3K27ac marks at the promoter and enhancer regions, correlate with active transcription in ALK-expressing cells.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The full-length ALK protein is a type I transmembrane receptor tyrosine kinase with a modular architecture comprising distinct functional domains from the N-terminus to the C-terminus [1, 3]:

1. **Signal Peptide (residues 1-18)**: Directs the nascent polypeptide to the endoplasmic reticulum for co-translational translocation into the secretory pathway.

2. **Extracellular Domain (residues 19-1038)**: This large domain mediates ligand binding and receptor dimerization. It contains:
   - **LDL-A domain (residues 19-49)**: A cysteine-rich region homologous to the ligand-binding domain of low-density lipoprotein receptor.
   - **MAM domains (residues 50-97 and 98-427)**: Two Meprin/A5-protein/PTPmu (MAM) domains that participate in protein-protein interactions and receptor dimerization.
   - **Glycine-rich region (residues 428-462)**: A flexible linker region.
   - **LDL-B domain (residues 463-490)**: A second LDL receptor class A domain.
   - **Immunoglobulin-like domains (residues 491-1038)**: Three immunoglobulin-like domains (Ig1, Ig2, Ig3) that are critical for ligand binding and receptor activation.

3. **Transmembrane Domain (residues 1039-1059)**: A single-pass hydrophobic alpha-helix that anchors the receptor in the plasma membrane.

4. **Juxtamembrane Domain (residues 1060-1116)**: Contains regulatory tyrosine residues and binding sites for intracellular signaling proteins.

5. **Intracellular Tyrosine Kinase Domain (residues 1116-1392)**: The catalytic domain responsible for tyrosine phosphorylation. This domain adopts the canonical bilobed structure of protein tyrosine kinases, with an N-terminal lobe (N-lobe) containing the P-loop and alpha-C helix, and a C-terminal lobe (C-lobe) containing the activation loop (A-loop) and catalytic loop.

6. **C-terminal Tail (residues 1393-1620)**: Contains multiple tyrosine phosphorylation sites that serve as docking sites for downstream signaling molecules.

### 2.2 Structural Biology of the Kinase Domain

The crystal structure of the ALK kinase domain (PDB: 3L9P) reveals a typical RTK fold with several unique features. The N-lobe consists of a five-stranded beta-sheet (β1-β5) flanked by the αC helix. The C-lobe contains six alpha-helices (αD-αI) and the activation loop. The ATP-binding pocket is located at the interface between the two lobes and is characterized by:

- **Hinge region**: Residues Glu1197-Met1199 form hydrogen bonds with ATP.
- **P-loop**: Residues Gly1123-Ser1131 form a glycine-rich phosphate-binding loop.
- **Catalytic loop**: Contains the conserved HRDLAARN motif (residues 1247-1254).
- **Activation loop**: Residues 1270-1295 contain the DFG motif (Asp1270-Phe1271-Gly1272) that regulates kinase activity.

A distinguishing feature of the ALK kinase domain is the presence of a unique insertion in the C-lobe between αE and αF helices that creates a hydrophobic pocket exploited by several ALK inhibitors [3].

### 2.3 Structural Basis of ALK Activation

ALK activation requires ligand-induced dimerization, which brings two kinase domains into close proximity, enabling trans-autophosphorylation of activation loop tyrosines [3]. The crystal structure of the ALK extracellular domain bound to its ligand (heparin or the growth factors FAM150A/B) reveals that ligand binding induces a conformational change that reorients the Ig domains, promoting receptor dimerization [3]. The juxtamembrane domain plays an autoinhibitory role in the basal state, and its phosphorylation relieves this inhibition.

### 2.4 Fusion Protein Architecture

In ALK fusion proteins, the extracellular and transmembrane domains are replaced by the oligomerization domain of the fusion partner. For example, in NPM-ALK, the NPM1 oligomerization domain (residues 1-117) mediates constitutive dimerization of the fusion protein, leading to ligand-independent activation of the ALK kinase domain [1, 8]. Similarly, EML4-ALK utilizes the coiled-coil domain of EML4 for constitutive oligomerization [5]. The fusion partner also determines the subcellular localization of the fusion protein: NPM-ALK localizes to both the nucleus and cytoplasm, while EML4-ALK is predominantly cytoplasmic.

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load ALK (PDB: 3L9P)](/tools/protein-structure-viewer?source=direct&pdbId=3L9P)

The interactive visualizer allows exploration of the ALK kinase domain structure, including the ATP-binding pocket, activation loop, and drug-binding sites. Users can rotate the structure, highlight specific residues, and overlay inhibitor binding modes.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Physiological Functions

ALK is a receptor tyrosine kinase that plays essential roles in the development and function of the nervous system [1, 3]. During embryonic development, ALK is expressed in specific regions of the central and peripheral nervous systems, where it regulates neuronal differentiation, axon guidance, and synapse formation. In the adult, ALK expression is largely restricted to subsets of neurons in the brain, with minimal expression in most other tissues [6].

The endogenous ligands for ALK include the growth factors FAM150A (augmentor-α) and FAM150B (augmentor-β), as well as heparin and related glycosaminoglycans [3]. Ligand binding induces receptor dimerization and activation of the intrinsic kinase activity, leading to autophosphorylation of specific tyrosine residues in the juxtamembrane region and C-terminal tail.

### 3.2 Oncogenic Signaling Pathways

In the context of oncogenic activation, ALK engages multiple downstream signaling cascades that promote cell proliferation, survival, migration, and metabolic reprogramming [1, 4, 9]:

#### 3.2.1 JAK-STAT Pathway
ALK directly phosphorylates and activates signal transducer and activator of transcription 3 (STAT3) and STAT5 [1, 2]. NPM-ALK binds to JAK3, which phosphorylates STAT3 at Tyr705, leading to its dimerization and nuclear translocation. STAT3 drives transcription of anti-apoptotic genes including BCL-2, BCL-XL, MCL-1, and survivin. STAT3 also upregulates the expression of the oncogenic transcription factor JUNB, which contributes to cell cycle progression in ALK+ ALCL [3, 4].

#### 3.2.2 PI3K/AKT/mTOR Pathway
ALK activates phosphatidylinositol 3-kinase (PI3K) through direct binding of the p85 regulatory subunit to phosphorylated tyrosine residues in the C-terminal tail. PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which recruits AKT to the plasma membrane where it is activated by PDK1 and mTORC2. Activated AKT phosphorylates multiple substrates, including TSC2, leading to mTORC1 activation and increased protein synthesis and cell growth [3].

#### 3.2.3 RAS/MAPK Pathway
ALK activates the RAS-MAPK pathway through the adaptor proteins SHC and GRB2, which recruit the guanine nucleotide exchange factor SOS to activate RAS. RAS activates the RAF-MEK-ERK cascade, leading to ERK-mediated phosphorylation of transcription factors such as ELK-1 and c-FOS that drive proliferation [4].

#### 3.2.4 PLCγ Pathway
ALK phosphorylates phospholipase C-γ (PLCγ), which hydrolyzes PIP2 to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC), contributing to cell survival and proliferation.

#### 3.2.5 MYCN Regulation
In neuroblastoma, ALK signaling regulates the expression of MYCN, a master transcription factor that drives tumor cell proliferation [4]. ALK activates MYCN transcription through both STAT3-dependent and STAT3-independent mechanisms. This establishes a positive feedback loop where ALK and MYCN reinforce each other's expression, promoting aggressive tumor phenotypes.

### 3.3 Protein-Protein Interaction Networks

The ALK interactome is complex and context-dependent. Key interacting proteins include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| NPM1 | Fusion partner | Constitutive oligomerization and kinase activation |
| EML4 | Fusion partner | Constitutive oligomerization and kinase activation |
| SHC1 | Adaptor protein | RAS-MAPK pathway activation |
| GRB2 | Adaptor protein | RAS-MAPK pathway activation |
| PI3K p85 | Regulatory subunit | PI3K-AKT pathway activation |
| STAT3 | Transcription factor | JAK-STAT pathway activation |
| JAK3 | Tyrosine kinase | STAT3 phosphorylation |
| PLCγ | Phospholipase | Calcium signaling |
| MYCN | Transcription factor | Transcriptional regulation |
| TRAF1 | Fusion partner | NF-κB pathway activation |
| CLTC | Fusion partner | Constitutive oligomerization |
| ATIC | Fusion partner | Constitutive oligomerization |
| TPM3 | Fusion partner | Constitutive oligomerization |
| RNF213 | Fusion partner | Constitutive oligomerization |

### 3.4 Regulatory Feedback Loops

ALK signaling is subject to multiple negative feedback mechanisms. The protein tyrosine phosphatases SHP-1 and PTPN1 dephosphorylate ALK and attenuate downstream signaling [5]. In ALK+ ALCL, loss of these phosphatases contributes to resistance to ALK inhibitors [5]. Additionally, ALK signaling induces the expression of suppressors of cytokine signaling (SOCS) proteins that inhibit JAK-STAT signaling.

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant L as "Ligand (FAM150A/B)"
    participant R as "ALK Receptor"
    participant J as "JAK3"
    participant S as "STAT3"
    participant P as "PI3K"
    participant A as "AKT"
    participant M as "mTOR"
    participant E as "ERK"
    participant N as "MYCN"
    participant C as "Cell Proliferation/Survival"
    L->>R: Ligand binding
    R->>R: Dimerization & autophosphorylation
    R->>J: Phosphorylation & activation
    J->>S: Phosphorylation (Tyr705)
    S->>S: Dimerization & nuclear translocation
    S->>C: Transcription of anti-apoptotic genes
    R->>P: Recruitment & activation
    P->>A: PIP3 production & AKT activation
    A->>M: TSC2 phosphorylation & mTORC1 activation
    M->>C: Protein synthesis & cell growth
    R->>E: RAS-MAPK cascade activation
    E->>N: MYCN transcription
    N->>C: Proliferation & survival
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ALK Fusions

ALK fusions are the most common oncogenic alterations involving the gene. The fusion partners and associated malignancies include:

| **Fusion Partner** | **Malignancy** | **Frequency** | **Reference** |
|---|---|---|---|
| NPM1 | ALCL | ~80% of ALK+ ALCL | [1, 8] |
| EML4 | NSCLC | ~3-7% of NSCLC | [5] |
| CLTC | ALCL, IMT | Rare | [6, 7] |
| ATIC | ALCL | Rare | [8, 9] |
| TPM3 | ALCL, IMT | Rare | [1, 2] |
| RNF213 | ALCL | Rare | [1] |
| TRAF1 | ALCL | Rare | [3] |
| STRN | Papillary thyroid carcinoma | Rare | [4] |
| KIF5B | NSCLC | Rare | [6] |
| TFG | ALCL, IMT | Rare | [2] |
| SEC31A | IMT | Rare | [2] |
| CARS | IMT | Rare | [2] |
| RANBP2 | Epithelioid IMT | Rare | [5] |

The EML4-ALK fusion in NSCLC is the most clinically significant ALK alteration due to its prevalence and therapeutic targetability [5]. EML4-ALK fusions occur predominantly in younger, never-smoker patients with adenocarcinoma histology [6, 7]. The fusion results from an inversion on chromosome 2p that juxtaposes the 5' portion of EML4 with the 3' portion of ALK, placing the ALK kinase domain under the control of the EML4 promoter and conferring constitutive oligomerization through the EML4 coiled-coil domain [5].

ALK fusions have also been identified in pediatric melanoma arising within giant congenital melanocytic nevi [2], mesothelioma in children and young adults [8], radiation-related papillary thyroid carcinoma [4, 9], inflammatory myofibroblastic tumors [1, 2, 3, 4], and various other malignancies [5, 6, 7, 8, 9].

### 4.2 Point Mutations

ALK point mutations are less common than fusions but are clinically significant in several contexts:

#### 4.2.1 Neuroblastoma
Germline and somatic mutations in the ALK kinase domain are found in approximately 8-10% of neuroblastoma cases [5]. The most common mutations include:
- **F1174L**: Located in the activation loop, this mutation increases kinase activity and confers resistance to crizotinib.
- **F1174C**: Reported in small cell carcinoma of the prostate, this mutation is sensitive to alectinib [1].
- **R1275Q**: Located in the kinase domain, this is the most common germline mutation in familial neuroblastoma.
- **G1128A**: Located in the P-loop, this mutation increases kinase activity.

#### 4.2.2 NSCLC
ALK point mutations in NSCLC are primarily acquired resistance mutations that emerge during TKI therapy [2, 6]. Common resistance mutations include:
- **C1156Y**: Located in the N-lobe, confers resistance to crizotinib.
- **L1196M**: The "gatekeeper" mutation, analogous to T790M in EGFR, confers resistance to crizotinib.
- **G1269A**: Located in the C-lobe, confers resistance to crizotinib.
- **S1206Y**: Located in the C-lobe, confers resistance to crizotinib.
- **I1171N/T**: Located in the C-lobe, confers resistance to crizotinib and ceritinib.
- **G1202R**: Located in the solvent front, confers resistance to crizotinib, ceritinib, and alectinib.
- **F1174C/V**: Located in the activation loop, confers variable resistance to different TKIs.

#### 4.2.3 Other Malignancies
ALK mutations have been reported in other cancers, including:
- **Schizophrenia-associated polymorphisms**: Nonsynonymous polymorphisms Arg1491Lys and Glu1529Asp have been associated with schizophrenia in a Japanese population [3].
- **Ovarian high-grade serous carcinoma**: ALK overexpression without gene rearrangement is associated with aggressive tumor phenotypes [4, 5].

### 4.3 Copy Number Alterations

ALK gene amplification and copy number gain have been reported in several malignancies:
- **Inflammatory breast cancer**: ALK copy number gain is present in a subset of cases and may have prognostic implications [6, 7].
- **Pulmonary sarcomatoid carcinoma**: Nonrandom amplification of the ALK gene has been described [8].
- **Neuroblastoma**: ALK copy number gain is observed in a subset of tumors [9].
- **ALK+ ALCL**: Copy number gain of the rearranged ALK gene is associated with variant fusions [1].

### 4.4 Partial Deletions and Complex Rearrangements

Partial deletions of the ALK gene have been reported in ALK+ ALCL [1]. Complex karyotypes with cryptic ALK insertions have been described in ALK+ large B-cell lymphoma [6, 7]. These complex rearrangements can complicate molecular diagnosis and require comprehensive cytogenetic analysis.

### 4.5 ClinVar Classifications

ClinVar contains numerous ALK variants with varying clinical classifications. Pathogenic and likely pathogenic variants are predominantly located in the kinase domain and include both germline (associated with neuroblastoma predisposition) and somatic (associated with acquired resistance) mutations. Variants of uncertain significance (VUS) are common throughout the gene, reflecting the need for functional characterization.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Epstein-Barr Virus (EBV)

The relationship between ALK and Epstein-Barr virus (EBV) has been investigated in the context of lymphomas. Primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis show absence of both ALK and EBV gene products, suggesting that these entities are pathogenetically distinct from systemic ALK+ ALCL [2]. In contrast, EBV-positive diffuse large B-cell lymphoma can occasionally express ALK, though the clinical significance of this co-expression remains unclear.

### 5.2 Viral Oncoproteins and ALK Regulation

While no direct viral oncoprotein has been shown to interact with ALK, viral infections can indirectly modulate ALK signaling through inflammatory cytokines and growth factors. For example, EBV-encoded LMP1 can activate STAT3, which may synergize with ALK signaling in certain lymphoma contexts. However, direct evidence for viral modulation of ALK activity is limited.

### 5.3 Immune Evasion Mechanisms

ALK fusion proteins can modulate the tumor immune microenvironment. NPM-ALK has been shown to upregulate PD-L1 expression through STAT3-dependent mechanisms, contributing to immune evasion. Additionally, ALK signaling promotes the secretion of immunosuppressive cytokines such as [IL-10](/knowledge/bioinformatics/genes/immunology-checkpoints/il10-gene-structure-function-pathway) and TGF-β, which inhibit anti-tumor immune responses.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved ALK Inhibitors

| **Drug** | **Generation** | **Targets** | **Approved Indications** | **Key Features** |
|---|---|---|---|---|
| Crizotinib (Xalkori) | 1st | ALK, MET, ROS1 | ALK+ NSCLC | First-in-class; dual MET/ALK inhibitor [3] |
| Ceritinib (Zykadia) | 2nd | ALK, IGF-1R, InsR | ALK+ NSCLC (post-crizotinib and first-line) | 20x more potent than crizotinib; ASCEND trials [4, 5] |
| Alectinib (Alecensa) | 2nd | ALK, RET, GAK | ALK+ NSCLC (first-line and post-crizotinib) | High CNS penetration; ALINA adjuvant trial [1, 3, 6] |
| Brigatinib (Alunbrig) | 2nd | ALK, ROS1, EGFR | ALK+ NSCLC (post-crizotinib and first-line) | Active against multiple resistance mutations [8] |
| Lorlatinib (Lorbrena) | 3rd | ALK, ROS1 | ALK+ NSCLC (post-2nd gen TKI) | Macrocyclic inhibitor; active against G1202R |

### 6.2 Mechanisms of Action

ALK inhibitors compete with ATP for binding to the kinase domain, thereby blocking phosphorylation of downstream substrates. The binding modes differ among inhibitors:

- **Crizotinib**: A 2-aminopyridine derivative that binds in the ATP pocket in a DFG-in conformation, forming hydrogen bonds with hinge residues Glu1197 and Met1199 [3].
- **Ceritinib**: A pyrimidine-based inhibitor that binds with higher affinity to the ATP pocket and has improved selectivity for ALK over MET [4].
- **Alectinib**: A tetracyclic compound that binds to the ATP pocket with high selectivity for ALK and excellent brain penetration [6].
- **Brigatinib**: A dimethylphosphine oxide compound that is highly potent against ALK and active against many crizotinib-resistant mutants [8].
- **Lorlatinib**: A macrocyclic inhibitor designed to overcome resistance mutations, particularly G1202R, by adopting a compact conformation that fits within the ATP pocket even with bulky amino acid substitutions.

### 6.3 Resistance Mechanisms

Resistance to ALK inhibitors arises through multiple mechanisms [2, 6]:

#### 6.3.1 On-Target Resistance
- **Secondary ALK mutations**: Point mutations in the kinase domain that reduce drug binding affinity while preserving kinase activity. The most common include L1196M (gatekeeper), G1269A, C1156Y, and G1202R [2, 6].
- **ALK amplification**: Copy number gain of the rearranged ALK allele can overcome drug inhibition.

#### 6.3.2 Off-Target Resistance
- **Activation of bypass signaling pathways**: Upregulation of EGFR, KRAS, KIT, or IGF-1R signaling can circumvent ALK dependence [7].
- **Lineage plasticity**: In some cases, tumor cells undergo epithelial-to-mesenchymal transition (EMT) or neuroendocrine differentiation, reducing dependence on ALK signaling.
- **Tyrosine phosphatase dysregulation**: Loss of negative regulators such as SHP-1 enhances ALK signaling [5].

### 6.4 Investigational Agents and Combination Strategies

Several investigational approaches are being evaluated:
- **Next-generation ALK inhibitors**: Multiple compounds with improved activity against resistant mutants are in clinical development [9].
- **Combination with MEK inhibitors**: Co-targeting ALK and MEK may overcome resistance mediated by RAS-MAPK pathway reactivation.
- **Combination with HSP90 inhibitors**: HSP90 inhibitors promote degradation of ALK fusion proteins and may be effective against multiple resistance mechanisms.
- **Immunotherapy combinations**: Combining ALK inhibitors with immune checkpoint inhibitors is being explored, though the optimal sequencing remains unclear.
- **Gene therapy approaches**: siRNA-based strategies targeting ALK have shown preclinical efficacy [8, 9].

### 6.5 Pharmacokinetic Considerations and Drug-Drug Interactions

ALK inhibitors are substrates for [CYP3A4](/knowledge/bioinformatics/genes/medical-genetics/cyp3a4-gene-structure-function-pathway) and P-glycoprotein, making them susceptible to drug-drug interactions [1]. Crizotinib is a moderate CYP3A4 inhibitor, while ceritinib is a strong CYP3A4 inhibitor. Alectinib and brigatinib have lower potential for drug-drug interactions. Dose adjustments may be required when co-administered with strong CYP3A4 inhibitors or inducers [1].

### 6.6 Adverse Effects and Safety Profile

Postmarketing surveillance of ALK inhibitors has identified several class-specific adverse effects [2, 3, 4]:
- **Gastrointestinal toxicity**: Nausea, vomiting, diarrhea, and hepatotoxicity are common, particularly with crizotinib and ceritinib.
- **Cardiac toxicity**: QT interval prolongation and bradycardia have been reported.
- **Pulmonary toxicity**: Interstitial lung disease/pneumonitis is a rare but serious adverse effect, particularly with brigatinib.
- **Renal toxicity**: Renal cysts and acute kidney injury have been reported [4].
- **Endocrine effects**: Hypothyroidism and hyperglycemia may occur.

### 6.7 Clinical Management and Treatment Sequencing

The treatment landscape for ALK+ NSCLC has evolved rapidly [5, 6, 7]. Current guidelines recommend:
- **First-line therapy**: Alectinib or brigatinib are preferred over crizotinib due to superior efficacy and CNS penetration [6, 8].
- **Second-line therapy**: Lorlatinib is recommended for patients who progress on second-generation TKIs.
- **Adjuvant therapy**: The ALINA trial is evaluating alectinib in the adjuvant setting for stage IB-IIIA ALK+ NSCLC [6].
- **Brain metastasis management**: Second-generation TKIs with high CNS penetration (alectinib, brigatinib) are preferred for patients with brain metastases [6].

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 238 | Gene ID for ALK |
| Ensembl | ENSG00000171094 | Gene annotation |
| UniProt | Q9UMD1 | Protein sequence and annotation |
| RCSB PDB | 3L9P | Crystal structure of ALK kinase domain |
| OMIM | 105590 | Mendelian inheritance and phenotype |
| ClinVar | Various | Clinical variant classifications |
| COSMIC | Various | Somatic mutation catalog |
| STRING | Q9UMD1 | Protein-protein interaction network |
| BioGRID | 106673 | Physical and genetic interactions |
| Gene Ontology | GO:0004713 (protein tyrosine kinase activity); GO:0007169 (transmembrane receptor protein tyrosine kinase signaling pathway); GO:0007399 (nervous system development) | Functional annotations |
| Reactome | R-HSA-1226099 | Signaling pathway annotations |
| KEGG | hsa05223 | Non-small cell lung cancer pathway |

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Perkins, I. U., Tan, S. Y., McCalmont, T., Chou, P., Mully, T., Gerami, P., Pomerantz, J., Reyes-Múgica, M., Balkin, D. M., Kruse, L. L., Huang, B. J., Reichek, J., Gangopadhyay, N., Chiosea, S., Green, J., Chamlin, S., Frieden, I., Bastian, B., & Yeh, I. (2023). Melanoma in infants, caused by a gene fusion involving the anaplastic lymphoma kinase ALK. *Pigment Cell & Melanoma Research*. https://www.semanticscholar.org/paper/6b01f00b1c9b5af66aa01f4761aca47bd0028c77

[2] Morris, S., Kirstein, M., Valentine, M., Dittmer, K., Shapiro, D., Saltman, D., & Look, A. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. *Science*. https://www.semanticscholar.org/paper/d1c138eecb5bac2e856edcb597d289f5d69f5875

[3] Mian, I., Abdullaev, Z., Morrow, B., Kaplan, R., Gao, S., Mettienen, M., Schrump, D., Zgonc, V., Wei, J. S., Khan, J., Pack, S., & Hassan, R. (2019). Anaplastic lymphoma kinase (ALK) Gene Rearrangement in Children and Young Adults with Mesothelioma. *Journal of Thoracic Oncology*. https://www.semanticscholar.org/paper/ad1a185bca13018326b22e2f1e26b9743a921cd4

[4] Rossing, H. H., Grauslund, M., Urbanska, E., Melchior, L., Rask, C. K., Costa, J. C., Skov, B., Sørensen, J., & Santoni-Rugiu, E. (2013). Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. *BMC Research Notes*. https://www.semanticscholar.org/paper/7d6760e5dffe60552b4cc34351522e58232f33a2

[5] Arndt, A., Steinestel, K., Rump, A., Sroya, M., Bogdanova, T., Kovgan, L., Port, M., Abend, M., & Eder, S. (2018). Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation‐related human papillary thyroid carcinoma after the Chernobyl accident. *The Journal of Pathology: Clinical Research*. https://www.semanticscholar.org/paper/188fe33ccadaac7bde3efed2498e89b697273ff5

[6] van der Krogt, J.-A., V. Bempt, M., Ferreiro, J. F., Mentens, N., Jacobs, K., Pluys, U., Doms, K., Geerdens, E., Uyttebroeck, A., Pierre, P., Michaux, L., Devos, T., Vandenberghe, P., Tousseyn, T., Cools, J., & Wlodarska, I. (2017). Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene. *Haematologica*. https://www.semanticscholar.org/paper/9d9cff03c08a730caf4ab0be1bc5184fe8862e5b

[7] Tan, C. L., Lim, T., Lim, T., Tan, D., Chua, Y. W., Ang, M., Pang, B., Lim, C., Takano, A., Lim, A., Leong, M., & Lim, W. (2016). Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. *OncoTarget*. https://www.semanticscholar.org/paper/720a1abca46e7c96297c7822c8dcf62556b19ef0

[8] Pot, A., Qing, D., Camidge, S., Kono, S., Flacco, A., Tan, A., Doebele, R., Crinò, L., Franklin, W., & Varella-Garcia, M. (2010). Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment. *Clinical Cancer Research*. https://www.semanticscholar.org/paper/63a0a0a8fc1aeb3e6562d9d5ef23d5c755ce37d6

[9] Alese, O., El-Rayes, B., Sica, G., Zhang, G., Alexis, D., La Rosa, F. L., Varella-Garcia, M., Chen, Z., Rossi, M., Adsay, N. V., Khuri, F., & Owonikoko, T. (2015). Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. *Therapeutic Advances in Medical Oncology*. https://www.semanticscholar.org/paper/bf517